Seegene received FDA emergency use authorization for Allplex HSV-1&2/VZV/MPXV, a multiplex real-time PCR assay intended to detect and differentiate herpes simplex virus, varicella-zoster virus, and mpox from ulcerative skin lesions. The company said the assay addresses diagnostic ambiguity when clinicians test only one pathogen at a time. Seegene highlighted its high-multiplex PCR technology stack and said the authorization expands Seegene USA’s ability to develop locally relevant multiplex diagnostic products for U.S. clinical labs and public health needs.